TIDMSLN

RNS Number : 8091V

Silence Therapeutics PLC

19 April 2021

Purchase of American Depositary Shares and PDMR Dealings

19(th) April 2021

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that, on 16 April 2021 the following purchases of American Depositary Shares ("ADSs"), each representing three ordinary shares of 5 pence each in the capital of the Company ("Ordinary Shares"), were made by persons discharging managerial responsibilities at a purchase price of $23.09 per ADS: 4,331 ADSs were purchased by Steven Romano, Non-Executive Director of the Company, 4,331 ADSs were purchased by Michael Davidson, MD, Non-Executive Director of the Company, 217 ADSs were purchased by Dave Lemus, Non-Executive Director of the Company, 6,063 ADSs were purchased by Mark Rothera, Chief Executive Officer and Executive Director of the Company and 8,662 ADSs were purchased by Craig Tooman, Chief Financial Officer of the Company.

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018, provide further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1.   Details of the person discharging managerial responsibilities 
       (PDMR) / person closely associated 
 a)   Name                         Steven Romano 
     ---------------------------  ----------------------------------------- 
 2.   Reason for the notification 
     ---------------------------------------------------------------------- 
 a)   Position / status            Non-Executive Director 
     ---------------------------  ----------------------------------------- 
 b)   Initial notification         Initial notification 
       / Amendment 
     ---------------------------  ----------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ---------------------------------------------------------------------- 
 a)   Name                         Silence Therapeutics plc 
     ---------------------------  ----------------------------------------- 
 b)   LEI                          213800SSURRJBX85SQ91 
     ---------------------------  ----------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ---------------------------------------------------------------------- 
 a)   Description of               American Depositary Shares (ADSs) , each 
       the financial instrument,    of which represents three (3) Ordinary 
       type of instrument           Shares of 5 pence each in the capital 
                                    of Silence Therapeutics plc 
 
 
 
 
       Identification               ISIN for Silence Therapeutics plc ADSs: 
       code                         US82686Q1013 
     ---------------------------  ----------------------------------------- 
 b)   Nature of the transaction    Purchase of ADSs in Silence Therapeutics 
                                    plc 
     ---------------------------  ----------------------------------------- 
 c)   Price(s) and volume(s)         Price    Volume 
                                      $23.09   4,331 
                                              ------- 
     ---------------------------  ----------------------------------------- 
 d)   Aggregated information 
       - Aggregated volume           4,331 ADSs 
       - Price                       $100,002.79 
     ---------------------------  ----------------------------------------- 
 e)   Date of the transaction      16 April 2021 
     ---------------------------  ----------------------------------------- 
 f)   Place of the transaction     Outside a trading venue 
     ---------------------------  ----------------------------------------- 
 
 
 1.   Details of the person discharging managerial responsibilities 
       (PDMR) / person closely associated 
 a)   Name                         Michael Davidson 
     ---------------------------  ----------------------------------------- 
 2.   Reason for the notification 
     ---------------------------------------------------------------------- 
 a)   Position / status            Non-Executive Director 
     ---------------------------  ----------------------------------------- 
 b)   Initial notification         Initial notification 
       / Amendment 
     ---------------------------  ----------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ---------------------------------------------------------------------- 
 a)   Name                         Silence Therapeutics plc 
     ---------------------------  ----------------------------------------- 
 b)   LEI                          213800SSURRJBX85SQ91 
     ---------------------------  ----------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ---------------------------------------------------------------------- 
 a)   Description of               American Depositary Shares (ADSs) , each 
       the financial instrument,    of which represents three (3) Ordinary 
       type of instrument           Shares of 5 pence each in the capital 
                                    of Silence Therapeutics plc 
 
 
       Identification 
       code                         ISIN for Silence Therapeutics plc ADSs: 
                                    US82686Q1013 
     ---------------------------  ----------------------------------------- 
 b)   Nature of the transaction    Purchase of ADSs in Silence Therapeutics 
                                    plc 
     ---------------------------  ----------------------------------------- 
 c)   Price(s) and volume(s)         Price    Volume 
                                      $23.09   4,331 
                                              ------- 
     ---------------------------  ----------------------------------------- 
 d)   Aggregated information 
       - Aggregated volume           4,331 ADSs 
       - Price                       $100,002.79 
     ---------------------------  ----------------------------------------- 
 e)   Date of the transaction      16 April 2021 
     ---------------------------  ----------------------------------------- 
 f)   Place of the transaction     Outside a trading venue 
     ---------------------------  ----------------------------------------- 
 
 
 1.   Details of the person discharging managerial responsibilities 
       (PDMR) / person closely associated 
 a)   Name                         Dave Lemus 
     ---------------------------  ----------------------------------------- 
 2.   Reason for the notification 
     ---------------------------------------------------------------------- 
 a)   Position / status            Non-Executive Director 
     ---------------------------  ----------------------------------------- 
 b)   Initial notification         Initial notification 
       / Amendment 
     ---------------------------  ----------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ---------------------------------------------------------------------- 
 a)   Name                         Silence Therapeutics plc 
     ---------------------------  ----------------------------------------- 
 b)   LEI                          213800SSURRJBX85SQ91 
     ---------------------------  ----------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ---------------------------------------------------------------------- 
 a)   Description of               American Depositary Shares (ADSs), each 
       the financial instrument,    of which represents three (3) Ordinary 
       type of instrument           Shares of 5 pence each in the capital 
                                    of Silence Therapeutics plc 
 
 
       Identification 
       code                         ISIN for Silence Therapeutics plc ADSs: 
                                    US82686Q1013 
     ---------------------------  ----------------------------------------- 
 b)   Nature of the transaction    Purchase of ADSs in Silence Therapeutics 
                                    plc 
     ---------------------------  ----------------------------------------- 
 c)   Price(s) and volume(s)         Price    Volume 
                                      $23.09   217 
                                              ------- 
     ---------------------------  ----------------------------------------- 
 d)   Aggregated information 
       - Aggregated volume           217 ADSs 
       - Price                       $5,010.53 
     ---------------------------  ----------------------------------------- 
 e)   Date of the transaction      16 April 2021 
     ---------------------------  ----------------------------------------- 
 f)   Place of the transaction     Outside a trading venue 
     ---------------------------  ----------------------------------------- 
 
 
 1.   Details of the person discharging managerial responsibilities 
       (PDMR) / person closely associated 
 a)   Name                         Mark Rothera 
     ---------------------------  ----------------------------------------- 
 2.   Reason for the notification 
     ---------------------------------------------------------------------- 
 a)   Position / status            Chief Executive Officer and Executive 
                                    Director 
     ---------------------------  ----------------------------------------- 
 b)   Initial notification         Initial notification 
       / Amendment 
     ---------------------------  ----------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ---------------------------------------------------------------------- 
 a)   Name                         Silence Therapeutics plc 
     ---------------------------  ----------------------------------------- 
 b)   LEI                          213800SSURRJBX85SQ91 
     ---------------------------  ----------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ---------------------------------------------------------------------- 
 a)   Description of               American Depositary Shares (ADSs) , each 
       the financial instrument,    of which represents three (3) Ordinary 
       type of instrument           Shares of 5 pence each in the capital 
                                    of Silence Therapeutics plc 
 
 
       Identification 
       code                         ISIN for Silence Therapeutics plc ADSs: 
                                    US82686Q1013 
     ---------------------------  ----------------------------------------- 
 b)   Nature of the transaction    Purchase of ADSs in Silence Therapeutics 
                                    plc 
     ---------------------------  ----------------------------------------- 
 c)   Price(s) and volume(s)         Price    Volume 
                                      $23.09   6,063 
                                              ------- 
     ---------------------------  ----------------------------------------- 
 d)   Aggregated information 
       - Aggregated volume           6,063 ADSs 
       - Price                       $139,994.67 
     ---------------------------  ----------------------------------------- 
 e)   Date of the transaction      16 April 2021 
     ---------------------------  ----------------------------------------- 
 f)   Place of the transaction     Outside a trading venue 
     ---------------------------  ----------------------------------------- 
 
 
 1.   Details of the person discharging managerial responsibilities 
       (PDMR) / person closely associated 
 a)   Name                         Craig Tooman 
     ---------------------------  ----------------------------------------- 
 2.   Reason for the notification 
     ---------------------------------------------------------------------- 
 a)   Position / status            Chief Financial Officer 
     ---------------------------  ----------------------------------------- 
 b)   Initial notification         Initial notification 
       / Amendment 
     ---------------------------  ----------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ---------------------------------------------------------------------- 
 a)   Name                         Silence Therapeutics plc 
     ---------------------------  ----------------------------------------- 
 b)   LEI                          213800SSURRJBX85SQ91 
     ---------------------------  ----------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ---------------------------------------------------------------------- 
 a)   Description of               American Depositary Shares (ADSs) , each 
       the financial instrument,    of which represents three (3) Ordinary 
       type of instrument           Shares of 5 pence each in the capital 
                                    of Silence Therapeutics plc 
 
 
       Identification 
       code                         ISIN for Silence Therapeutics plc ADSs: 
                                    US82686Q1013 
     ---------------------------  ----------------------------------------- 
 b)   Nature of the transaction    Purchase of ADSs in Silence Therapeutics 
                                    plc 
     ---------------------------  ----------------------------------------- 
 c)   Price(s) and volume(s)         Price    Volume 
                                      $23.09   8,662 
                                              ------- 
     ---------------------------  ----------------------------------------- 
 d)   Aggregated information 
       - Aggregated volume           8,662 ADSs 
       - Price                       $200,005.58 
     ---------------------------  ----------------------------------------- 
 e)   Date of the transaction      16 April 2021 
     ---------------------------  ----------------------------------------- 
 f)   Place of the transaction     Outside a trading venue 
     ---------------------------  ----------------------------------------- 
 

Enquiries:

 
 Silence Therapeutics plc                              Tel: +1 (646) 637-3208 
  Gem Hopkins, Head of IR & Corporate Communications 
  Investec Bank plc (Nominated Adviser and              Tel: +44 (0) 20 
   Broker)                                               7597 5970 
   Daniel Adams/Gary Clarence 
 European PR                                           Tel: +44 (0) 20 
  Consilium Strategic Communications                    3709 5700 
  Mary-Jane Elliott/Chris Welsh/Angela Gray 
  silencetherapeutics@consilium-comms.com 
 
 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD(TM) platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFZGMDGRKGMZZ

(END) Dow Jones Newswires

April 19, 2021 02:00 ET (06:00 GMT)

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Silence Therapeutics Charts.
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Silence Therapeutics Charts.